Author Archives: Richard Denison

EPA IRIS program requests conflict-of-interest disclosures by commenters

Richard Denison, Ph.D.is a Lead Senior Scientist.  Lindsay McCormick is a Research Analyst

EPA’s Integrated Risk Information System (IRIS) is now requesting that persons who make oral comments at its bimonthly meetings or submit written comments on its documents disclose whether they have “financial relationships … with any organization(s) or entities having an interest in the assessments or issues under discussion,” and, if so, to identify the nature of that relationship, (e.g., consulting agreements, expert witness support, or research funding).   Read More »

Posted in Health Policy, Industry Influence| Tagged , | Leave a comment

Whither TSCA reform post-election?

Richard Denison, Ph.D., is a Lead Senior Scientist.

[This post is adapted from comments I gave at a recent Friday Forum hosted by the American Bar Association’s Pesticides, Chemical Regulation and Right-to-Know Committee.]

Elections change some things and don’t change others.  That is certainly true about what happened on Nov 4.

The best election recap I’ve heard came from a hairdresser I overhead when getting my hair cut last week.  She said:  “Democrats win, I have to work; Republicans win, I have to work.”

I doubt anyone would try to argue that the election was in any way about or directly relevant to the TSCA reform debate, or even any sort of more general referendum on the environment.  My view is that it wasn’t really even much about political parties and which one controls the Senate – it was more of a “throw the bums out and let some new ones have a try” election.

On the other hand, it was about broad and deep dissatisfaction of voters with the inability of Washington to get anything meaningful done.  That is relevant to the opportunity the TSCA reform issue presents to the new Congress, which is one of a handful of issues that seems to have the potential to show voters that something can get done.

There is also no question that the dynamics that have determined for some time the pace and direction of the TSCA reform debate changed significantly with the switch to Republican control of the Senate. That brings with it new political opportunities and challenges.

But what I want to talk mostly about is what HASN’T changed.  Read More »

Posted in Health Policy, TSCA Reform| Tagged | Leave a comment

EDF’s recommendations for IRIS conflicts-of-interest disclosures, and the strong precedents for them

Richard Denison, Ph.D., is a Lead Senior Scientist.  Lindsay McCormick is a Research Analyst

Our last blog post was quite lengthy and some readers may not have gotten to the recommendations we provided to EPA’s Integrated Risk Information System (IRIS) governing disclosures of conflicts of interest.  In that post, we also cited the numerous strong precedents for requiring such disclosures.

So we’re reposting here our recommendations and discussion of precedents.   Read More »

Posted in Health Policy, Industry Influence| Tagged , , | Comments closed

Time to come clean: IRIS needs to require stakeholders attending its meetings to disclose their conflicts of interest

Richard Denison, Ph.D., is a Lead Senior Scientist.  Lindsay McCormick is a Research Analyst.  

EPA’s Integrated Risk Information System (IRIS) has been implementing a number of changes in the last couple of years, in response to criticism and concerns coming at it from all sides.  As stated on its website:  “These enhancements will improve productivity and scientific quality in IRIS assessments and help EPA meet the goal of producing IRIS assessments in a timely and transparent manner.”  IRIS has noted that increasing “stakeholder engagement is an essential part of the enhancements.”

Simultaneously pursuing these lofty goals of increasing throughput, scientific quality, transparency and stakeholder engagement in IRIS assessments is challenging, to say the least.  EDF has and will continue to emphasize the need to strike a balance between these goals, given that overemphasis on one can actually exacerbate the problems aimed to be addressed by another.

In this somewhat lengthy post, we’ll examine one such serious problem – skewed participation in IRIS’ bimonthly meetings.  We’ll look at steps EPA has taken to partially address the problem, and argue that the lack of adequate disclosure by participants of conflicts of interest remains a major unaddressed contributing factor.  We’ll discuss our recommendations for full disclosure and point to the strong precedents for such disclosures in other venues.   Read More »

Posted in EPA, Health Policy, Industry Influence| Tagged , , | Comments closed

Will 2015 be the year of full product ingredient disclosure?

Richard Denison, Ph.D., is a Lead Senior Scientist.

Michelle Harvey, Jennifer McPartland and Boma Brown-West contributed to this post.

[UPDATE 10/28/14:  This post has been updated to reflect information we learned since posting it, regarding additional companies' disclosure initiatives.]

We are nowhere near New Year’s Day, but based on recent corporate resolutions, 2015 is shaping up to be the year for ingredient transparency in products!  And that’s good news for those of us who want to know what we may be exposing ourselves and our families to when we use everyday products in our homes and on our bodies.

Unlike food and drugs, which must bear content labels, there has all too often been no way for consumers to know what’s in the products they use.  In particular, the composition of the myriad fragrances used in household cleaners, detergents and soaps, air fresheners, and other common household products have pretty much been a black box.  But change is on the way.   Read More »

Posted in Health Policy, Markets and Retail| Tagged | Comments closed

What’s the path forward on TSCA reform?

Richard Denison, Ph.D., is a Lead Senior Scientist.

Links to blog posts in this series:  Part 1     Part 2     Part 3

With two proposals to reform the Toxic Substances Control Act (TSCA) now, more or less, on the streets, and with some time to contemplate what course reform efforts might follow, it is important to consider what it will take to actually pass legislation into law.

Regardless of what happens in the elections this November, the only viable path forward I see is a strongly bipartisan one. The negotiations over the Chemical Safety Improvement Act (CSIA) during the past year and a half have broken through some longstanding impasses.  As I’ve noted earlier, EDF believes the Udall-Vitter proposal (which does not resolve the difficult issue of preemption) fixes the key flaws in current TSCA – and does so in ways that both Democrats and Republicans can support.

Chairman Boxer has publicly released her own substantive reform proposal, in the form of a redline of the Udall-Vitter proposal.  In doing so, she raises important issues that, in addition to preemption, need to be addressed.  Some of her proposals seem relatively easy to reconcile with Udall-Vitter, and some do not.  For the record, the latter include a number of provisions EDF has supported.

With respect to federal policy and EPA authority, both the Udall-Vitter and Boxer proposals would dramatically improve upon current law and would have a strong, positive impact on the health of the nation’s people and environment.

With two strong proposals on the table, I believe the conversation we need to be having now is how we get to a bill that can pass into law in a sharply divided Congress.  That’s because, to say it again, no matter what happens in November, this is going to need to be a bipartisan effort.  I remain confident we can address the failings of TSCA through provisions that can earn broad support.

Let me say up front that I believe any attempt to return to original CSIA as a result of a breakdown in negotiations would certainly be a step in the wrong direction and away from a bipartisan path forward.  Equally problematic would be a return to the Safe Chemicals Act, which failed to gain bipartisan support.

In the remainder of this post, I'll take a look at the Boxer proposal.

Read More »

Posted in Health Policy, TSCA Reform| Tagged | Comments closed
  • About this blog


    Science, health, and business experts at Environmental Defense Fund comment on chemical and nanotechnology issues of the day.
    Our work: Chemicals
  • Categories

  • Get blog posts by email

    Subscribe via RSS

  • Filter posts by tags

    • aggregate exposure (10)
    • Alternatives assessment (3)
    • American Chemistry Council (ACC) (57)
    • arsenic (3)
    • asthma (3)
    • Australia (1)
    • biomonitoring (9)
    • bipartisan (6)
    • bisphenol A (19)
    • BP Oil Disaster (18)
    • California (1)
    • Canada (7)
    • carbon nanotubes (24)
    • carcinogen (22)
    • Carcinogenic Mutagenic or Toxic for Reproduction (CMR) (12)
    • CDC (6)
    • Chemical Assessment and Management Program (ChAMP) (13)
    • chemical identity (30)
    • chemical testing (1)
    • Chemicals in Commerce Act (3)
    • Chicago Tribune (6)
    • children's safety (23)
    • China (10)
    • computational toxicology (11)
    • Confidential Business Information (CBI) (53)
    • conflict of interest (7)
    • consumer products (48)
    • Consumer Specialty Products Association (CSPA) (4)
    • contamination (4)
    • cumulative exposure (4)
    • data requirements (46)
    • dermal exposure (1)
    • diabetes (4)
    • DNA methylation (4)
    • DuPont (11)
    • endocrine disruption (28)
    • epigenetics (4)
    • exposure and hazard (49)
    • FDA (8)
    • flame retardants (20)
    • formaldehyde (15)
    • front group (13)
    • general interest (22)
    • Globally Harmonized System (GHS) (5)
    • Government Accountability Office (5)
    • hazard (6)
    • High Production Volume (HPV) (22)
    • in vitro (14)
    • in vivo (11)
    • industry tactics (44)
    • informed substitution (1)
    • inhalation (18)
    • IUR/CDR (27)
    • Japan (3)
    • lead (6)
    • markets (1)
    • mercury (4)
    • methylmercury (2)
    • microbiome (3)
    • nanosilver (6)
    • National Academy of Sciences (NAS) (20)
    • National Institute for Occupational Safety and Health (NIOSH) (7)
    • National Institute of Environmental Health Sciences (NIEHS) (5)
    • National Nanotechnology Initiative (NNI) (7)
    • National Toxicology Program (1)
    • obesity (6)
    • Occupational Safety and Health Administration (OSHA) (3)
    • Office of Information and Regulatory Affairs (OIRA) (4)
    • Office of Management and Budget (OMB) (16)
    • Office of Pollution Prevention and Toxics (OPPT) (3)
    • oil dispersant (18)
    • PBDEs (16)
    • Persistent Bioaccumulative and Toxic (PBT) (22)
    • pesticides (7)
    • phthalates (17)
    • polycyclic aromatic hydrocarbons (PAH) (5)
    • prenatal (6)
    • prioritization (35)
    • report on carcinogens (1)
    • revised CSIA (4)
    • risk assessment (69)
    • Safe Chemicals Act (24)
    • Safer Chemicals Healthy Families (33)
    • Significant New Use Rule (SNUR) (20)
    • Small business (1)
    • South Korea (4)
    • styrene (6)
    • Substances of Very High Concern (SVHC) (15)
    • systematic review (1)
    • test rule (17)
    • tributyltin (3)
    • trichloroethylene (TCE) (3)
    • Turkey (3)
    • U.S. states (14)
    • vulnerable populations (1)
    • Walmart (2)
    • worker safety (23)
    • WV chemical spill (11)